US Kidney Research Corp Wins KidneyX Third Round International Contest
World's First Waterless Kidney Blood Purifying Device Wins Coveted 650k Prize
Roseville, CA (PRUnderground) October 7th, 2021
US Kidney Research Corporation is an award winner of the KidneyX Phase 1 third round Artificial Kidney Contest for its novel development of a dialysate-free waterless portable and implantable artificial kidney technology. The $650,000 prize is the largest KidneyX prize to date. Companies from around the world competed in the contest. Six companies were selected as winners. US kidney Research corporation also won the very first Phase 1 KidneyX Redesign Dialysis contest held in 2019.
Roland Ludlow, founder and CEO of US Kidney Research Corporation said, “Over the past five years, our researchers have been able to solve complex problems using novel advanced technology culminating into very successful results. The KidneyX prize will help further our progress. We are honored to be chosen as a recipient of their prestigious award”.
US Kidney Research Corporation, a leader in artificial kidney research, has created a portable functioning prototype. It is the only waterless blood purifying device in existence. The technology has the potential to completely replace current dialysis procedures.
- Unlike dialysis the new technology does not require purified water, dialysate solution, or a dialyzer to function. The device is simply hooked up to the bloodstream and creates synthetic urine.
- The technology doesn’t utilize cells or other biological components allowing the components in our devices to last significantly longer, not be prone to rejection, and to be controlled by computer algorithms.
- The technology can be miniaturized and used to make an implantable artificial kidney
- Dynamic feedback control using a sensor panel adjusts the filtration and transport properties of the device.
- Provides data in real time for improved treatment of patients.
US Kidney Research Corp is the first in the world to produce synthetic urine without using dialysis. The device produces “synthetic urine” which compensates for the impaired urine output of patients with kidney disease. The ability to produce synthetic urine, a major milestone, was demonstrated in large animals (pigs) lacking functional kidneys.
Dr. Ira Kurtz, Chief of Nephrology at the University of California (UCLA), whom is US Kidney Research Corporation’s Chief Medical/Science Advisor and a Board Member said, “Our technology represents the first major innovation in renal replacement therapy since hemodialysis was first invented in the 1940s. We predict it will be a gamechanger. Millions of patients worldwide will potentially benefit from our technology.”
Further development of the technology will include additional animal studies, testing for efficacy and safety, in preparation for future clinical trials to take place early next year.
About US Kidney Research Corporation
US Kidney Research Corporation (USKRC) is a Delaware C-Corp founded in June, 2015. USKRC is a leader in the field of artificial kidney research and involved in R&D of the world’s first waterless renal replacement technology.
Contrary to dialysis, their new technology does not require purified water, dialysate concentrate solutions, or a dialyzer, providing significant advantages for both the patient and provider. Their novel waterless blood purification technology is leading to the creation of a truly artificial kidney to replace dialysis and native kidney transplantation. Additionally, the same technology is being used to develop a portable wearable artificial kidney, a portable tabletop device, and ultimately an implantable artificial kidney.
USKRC is currently finishing their portable prototypes. The company says that with adequate funding their backpack and tabletop portable prototypes can be completed and ready for clinical trials within 2 to 2 1/2- years.
The company’s future plans include advancing their technology, miniaturizing their prototype for use in an implantable artificial kidney. The company is also advancing their new non-clotting filtering technology, PD dialysate regeneration, and studying the role of middle molecules (uremic toxins) including a method to detect, identify, and isolate them.
USKRC is working with Dr. Ira Kurtz, their Science/Medical Advisor/Board Member, whom also is the Chief of Nephrology at the University of California Los Angeles (UCLA) and with researchers from the Department of Chemical Engineering at the University of Arkansas, headed by Dr. Jamie Hestekin.